Drug interactions
Methylphenidate transdermal + Rasagiline
Severity: Contraindicated
Methylphenidate transdermal and Rasagiline: contraindicated interaction.
Last updated Sources: US FDA label
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Methylphenidate with MAO inhibitors can precipitate hypertensive crisis. The transdermal formulation is contraindicated during and within 14 days of MAO inhibitor therapy.
What this interaction means in plain words
Methylphenidate transdermal and Rasagiline are not normally used together. Taking them at the same time is expected to cause harm or make one of them unsafe, so a different medicine is usually chosen for one of the two.
Why it happens
Methylphenidate raises synaptic dopamine and norepinephrine and MAO inhibition blocks their degradation, causing additive pressor effects.
What to do
Avoid the combination and keep a 14-day gap after stopping the MAO inhibitor. Consider a non-stimulant alternative.
What to ask your pharmacist
- Is there an alternative to one of these two medicines for me?
- If both are essential, who is monitoring me and how often?
- Which symptoms mean I should stop and seek help straight away?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Methylphenidate transdermal and Rasagiline, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
References
Other interactions of Rasagiline
- Atomoxetine + Rasagiline Contraindicated
- Brimonidine + Rasagiline Contraindicated
- Bupropion-naltrexone + Rasagiline Contraindicated
- Bupropion + Rasagiline Contraindicated
- Clomipramine + Rasagiline Contraindicated
- Desvenlafaxine + Rasagiline Contraindicated
Frequently asked questions
Can I take Methylphenidate transdermal with Rasagiline?
MediHelp rates the interaction as contraindicated. Methylphenidate transdermal and Rasagiline are not normally used together. Taking them at the same time is expected to cause harm or make one of them unsafe, so a different medicine is usually chosen for one of the two. Methylphenidate with MAO inhibitors can precipitate hypertensive crisis. The transdermal formulation is contraindicated during and within 14 days of MAO inhibitor therapy.
How serious is the interaction between Methylphenidate transdermal and Rasagiline?
MediHelp rates it contraindicated, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination and keep a 14-day gap after stopping the MAO inhibitor. Consider a non-stimulant alternative.
What other medicines interact with Rasagiline?
MediHelp also lists interactions of Rasagiline with, for example, Atomoxetine, Brimonidine, Bupropion-naltrexone. The full list is on the Rasagiline page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
